Domain II Mutants Of Anthrax Lethal Factor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 29, 2008
app pub date -
Oct 3, 2005
filing date -
Oct 1, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A series of mutants of Anthrax lethal factor (LF) are disclosed which define a conformational epitope or region of the molecule that interacts with the LF target, the MEK enzyme. Such mutants or variants, and nucleic acids encoding them are disclosed. The knowledge of such binding, separate from recognition of MEK by the protease active site of LF, serves as the basis for novel screening assays for discovery of inhibitors of this additional form of LF-MEK binding which is necessary for ultimate proteolysis and toxicity. The nontoxic LF mutants are useful as immunogenic compositions for generating antibodies and a state of immunity specific for the LF component of a B. arithracis infection or exposure otherwise to the anthrax lethal toxin.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully